Login to Your Account



Other News To Note


Friday, April 6, 2012
• Zalicus Inc., of Cambridge, Mass., published preclinical data in Molecular Cancer Therapeutics showing that adenosine A2A and beta-2 adrenergic receptor agonists enhance glucocorticoid activity in B-cell malignancies like multiple myeloma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription